Press Release

AAF Research and Analysis on 340B Drug Pricing Program

ANDREW EVANS | JULY 9, 2018

As HHS Secretary Alex Azar will speak at the 340B Coalition conference today, American Action Forum’s extensive research on the history, mechanisms, and consequences of the 340B program may be helpful. Several of our recent pieces are below, for your reference.

- **Market Distortions Caused by the 340B Prescription Drug Program** – This research explains how the program’s rapid expansion has limited patient access to community-based providers, increasing the cost of care even as patients fail to benefit from the program’s discounts on drugs.

- **CMS Moves Toward Much-Needed 340B Reforms** – This analysis outlines the Trump Administration’s proposal last year to adjust reimbursement rates for Medicare patients who receive medications through the 340B program.

- **Reforming 340B** – This analysis outlines opportunities for reforming the 340B program to improve the integrity and sustainability of the program and to ensure its discounts actually reach the intended beneficiaries.

- **Understanding The 340B Drug Pricing Program** – This primer explains the structure and logic of the 340B program.